Korea’s CJ CheilJedang Corp. Under Police Investigation For Rebates
This article was originally published in PharmAsia News
Probes into CJ and Dong-A signal Korea’s anti-rebate stance won’t stop anytime soon.
You may also be interested in...
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.